Lower the hazard of relapse. Classification of proof: This study offers
Chemexpress Lower the hazard of relapse. Classification of proof: This study offers Class IV evidence that RRs aren’t higher in individuals with multiple sclerosis switching to fingolimod from natalizumab compared to…